EUROAPI, a pharmaceutical company has recently revealed its plans to invest €50 million in a new state-of-the-art production plant at its Budapest site. The investment aims to enhance the company's manufacturing capabilities and meet the growing demand for its products
The investment aims to expand the facility's capacity and meet the growing demand for prostaglandins.
The project will involve debottlenecking the current capacity and constructing new multi-purpose manufacturing equipment.
Prostaglandins are a dynamic component of the API market, with an annual sales market of approximately €5 billion.
EUROAPI is the only Western supplier with a complete portfolio of prostaglandins and a fully integrated production site in Europe.
The investment reinforces EUROAPI's commitment to serving the needs of clients in differentiated health product segments.
The new facility will reduce environmental impact through a modern air handling system, energy-efficient design, and closed waste handling.
It will also feature highly potent-API (HP-API) capabilities for potential future developments.
The prostaglandin market is projected to grow at a CAGR of 5-7% between 2022 and 2027.
The overall prostaglandin capacity of the Budapest site is expected to more than double by 2027.
The investment will be implemented in two phases: 2023-2025 and 2026-2027.